Serum Cholesterol in Patients with Obsessive Compulsive Disorder during Treatment with Behavior Therapy and SSRI or Placebo

Peter, Helmut; Tabrizian, Susanne; Hand, Iver

doi:10.2190/apwf-n1xu-y7a0-tcbw

Cited by 17 publications

(15 citation statements)

References 53 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies investigated the effect of FLV on plasma lipoprotein levels and reported that FLV may reduce serum cholesterol levels (51,52). In contrast, there have been few studies focused on the effect of plasma lipoprotein levels on FLV pharmacological effect.…”

Section: Discussionmentioning

confidence: 99%

Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats

Fukushima

Kobuchi²,

Shibata³

et al. 2011

J Pharm Pharm Sci

View full text Add to dashboard Cite

Purpose. Many clinical reports and trials have suggested that fluvoxamine (FLV) reduces plasma lipoprotein levels. However, few studies have reported the effect of plasma lipoproteins on FLV pharmacokinetics. The aim of the present study was to investigate the affinities of FLV to plasma lipoproteins and the effect of plasma lipoproteins on the biodistribution of FLV using an experimental hyperlipidemic (HL) rat model. Methods. HL rats were prepared by intraperitoneal administration of Poloxamer-407 solution (1.0 g/kg). In vitro protein binding and distribution of FLV in plasma lipoproteins were determined in control and HL rats. In vivo pharmacokinetic study (intravenous administration of FLV, 5.0 mg/kg) and biodistribution analysis for brain and liver at a steady state (infusion, 1.5 mg/kg/hr, 6 hrs) were also performed. Results. The plasma protein binding of FLV was around 83% and 95% in control and HL rats, respectively, whereas the FLV recoveries in triglyceride-rich lipoprotein fractions were increased in HL. Therefore, the elevation of lipoproteins was likely responsible for the increase in protein binding in HL. After intravenous administration, the area under the plasma concentration vs. time curve (AUC) in HL was 3.9-fold greater than that in control rats, whereas the distribution ratio of FLV plasma concentration to the brain at a steady state was decreased to approximately 20% of that of the control. Conclusions. FLV has an affinity to plasma lipoproteins, and their elevation might decrease the FLV biodistribution to brain; the plasma lipoprotein levels could not be found to correlate positively with the FLV pharmacokinetic effect in brain, but rather may attenuate it.

show abstract

Section: Discussionmentioning

confidence: 99%

Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats

Fukushima

Kobuchi²,

Shibata³

et al. 2011

J Pharm Pharm Sci

View full text Add to dashboard Cite

show abstract

“…Çalışmada anksiyete şiddeti ile serum lipid değerlerinin ilişkisini incelediğimizde, sadece LDL-kolesterol düzeyi ile anlamlı ilişki saptandı (p:0,031). Bizim çalışmamıza benzer şekilde anksiyete skoru ile serum lipid değerleri arasında anlamlı ilişki gösterilmiştir (46,47). Geniş çaplı bir araştırmada ise LDL-kolesterol düşüklüğü ile anksiyetenin şiddeti arasında anlamlı ilişki saptanmıştır (48).…”

Section: Gereç Ve Yöntemunclassified

Relationship Between Level Of Anxiety And Serum Lipid Profile In Patients Followed By Anxiety Disorder

Gürbüz¹,

Kara²,

Öngel³

2011

Tepecik Dergisi

View full text Add to dashboard Cite

AMAÇ:Anksiyete bozukluğu nedeni ile Psikiyatri Polikliniğinde izlemekte olduğumuz hastalarda serum lipid profili deği-şimi olup olmadığı araştırmak. GEREÇ VE YÖNTEM:Çalışma Süleyman Demirel Üniversitesi Tıp Fakültesi Psikiyatri polikliniğinde anksiyete bozukluğu tanısı alan ve kronik hastalığı (diabetes mellitus, hipertansiyon, koroner arter hastalığı, dislipidemi) olmayan hastalar ile Aile Hekimliği polikliniğine başvuran kontrol grubu üzerinde, Eylül 2009-Şubat 2010 tarihleri arasında yapılmıştır. Onam formunu imzalayarak çalışmayı kabul eden hastalara sosyodemografik veri anketi ve Hamilton Anksiyete Ölçeği testi uygulanmıştır. Ardından hastalara uygun oldukları bir gün en az 12 saatlik bir açlıktan sonra gelmeleri söylenerek serum lipid profilleri değerlendirilmiştir. BULGULAR:Çalışmaya 71'i kadın (%55,9), 56'sı erkek (%44,1) olmak üzere 127 kişi alındı. Panik bozukluk olan grupta; düşük dansiteli lipoprotein düzeyiyle (p:0.020), trigliserid düzeyi ile (p:0.046) ve total kolesterol düzeyi ile (p:0.038) Hamilton anksiyete puanı arasında anlamlı ilişki bulundu. Yaygın anksiyete bozukluğu grubunda; düşük dansiteli lipoprotein düzeyiyle (p:0.019); total kolesterol düzeyiyle (p:0.003) ve yüksek dansiteli lipoprotein düzeyleri ile (p:0.011) Hamilton anksiyete puanı arasında anlamlı ilişki saptandı. Obsesif kompulsif bozukluk grubunda; düşük dansiteli lipoprotein düzeyiyle Hastane anksiyete puanı (p:0.031) ve total kolesterol ile Hamilton anksiyete puanı (p:0.000) arasında anlamlı ilişki saptandı. Çalışmamızda bütün anksiyete alt gruplarında düşük dansiteli lipoprotein düzeyiyle Hamilton anksiyete puanı arasında anlamlı ilişki tespit edildi. SONUÇ:Anksiyete bozukluğu olan hastaların psikiyatrik kontrollerinin yanında, rutin olarak serum lipid profili de incelenerek, ileride gelişebilecek koroner arter hastalıkları azaltılabilir.

show abstract

“…Treatment with the SSRIs did not appear to result in increased cholesterol levels in one study (Bilici et al, 2001). In fact, the SSRIs appear to possess antihyperlipidemic effects (Bailey and LeMelledo, 2003;Peter et al, 2000;Sonawalla et al, 2001b). Treatment of depression with SSRIs was reported to decrease the activity of a number of antioxidative enzymes (glutathione reductase, glutathione peroxidase, malondialdehyde, superoxide dismutase) in one study (Bilici et al, 2001).…”

Section: Side-effect Profilementioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Serum Cholesterol in Patients with Obsessive Compulsive Disorder during Treatment with Behavior Therapy and SSRI or Placebo

Cited by 17 publications

References 53 publications

Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats

Decrease in Brain Distribution of Fluvoxamine in Experimental Hyperlipidemic Rats

Relationship Between Level Of Anxiety And Serum Lipid Profile In Patients Followed By Anxiety Disorder

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About